Accumulation of advanced oxidation protein products induces podocyte apoptosis and deletion through NADPH-dependent mechanisms

Kidney International

Volumn 76, Issue 11, 2009, Pages 1148-1160

  Li Zhou, Li ^a   Hou, Fan Fan ^a   Wang, Guo Bao ^a   Yang, Fang ^a   Xie, Di ^a   Wang, Yong Ping ^a   Tian, Jian Wei ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

AOPPs; NADPH oxidase; Podocyte apoptosis; Podocyte depletion

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ADVANCED OXIDATION PROTEIN PRODUCT; APOCYNIN; BIOLOGICAL MARKER; CASPASE 3; DIMETHADIONE; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ALBUMINURIA; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL LOSS; CELL STRUCTURE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFECT; ENZYME ACTIVITY; GLOMERULOSCLEROSIS; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASE; NICK END LABELING; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; PROTEINURIA; RAT; SPRAGUE DAWLEY RAT; UPREGULATION; URINARY EXCRETION;

EID: 72949091681     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.322     Document Type: Article

References (67)

1. Kitada M, Koya D, Sugimoto T et al. Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy. Diabetes 2003; 52: 2603-2614.
2. Choudhuri T, Pal S, Agwarwal ML et al. Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction. FEBS Lett 2002; 512: 334-340.
3. Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996; 7: 2495-2508.
4. Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 2002; 136: 604-615.
5. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 2003; 83: 253-307.
6. Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 1998; 54: 687-697.
7. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54: 1626-1634.
8. Toyoda M, Najafian B, Kim Y et al. Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes 2007; 56: 2155-2160.
9. White KE, Bilous RW. Structural alterations to the podocyte are related to proteinuria in type 2 diabetic patients. Nephrol Dial Transplant 2004; 19: 1437-1440.
10. Pagtalunan ME, Miller PL, Jumping-Eagle S et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99: 342-348.
11. Steffes MW, Schmidt D, McCrery R et al. Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int 2001; 59: 2104-2113.
12. Lemley KV, Lafayette RA, Safai M et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int 2002; 61: 1475-1485.
13. Lemley KV, Lafayette RA, Derby G et al. Prediction of early progression in recently diagnosed IgA nephropathy. Nephrol Dial Transplant 2008; 23: 213-222.
14. Schiffer M, Bitzer M, Roberts IS et al. Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 2001; 108: 807-816.
15. Schiffer M, Mundel P, Shaw AS et al. A novel role for the adaptor molecule CD2-associated protein in transforming growth factor-beta-induced apoptosis. J Biol Chem 2004; 279: 37004-37012.
16. Susztak K, Raff AC, Schiffer M et al. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006; 55: 225-233.
17. Ding G, Reddy K, Kapasi AA et al. Angiotensin II induces apoptosis in rat glomerular epithelial cells. Am J Physiol Renal Physiol 2002; 283: F173-F180.
18. Marshall CB, Pippin JW, Krofft RD et al. Puromycin aminonucleoside induces oxidant-dependent DNA damage in podocytes in vitro and in vivo. Kidney Int 2006; 70: 1962-1973.
19. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-1313.
20. Witko-Sarsat V, Friedlander M, Nguyen KT et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-2532.
21. Kalousova M, Skrha J, Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 2002; 51: 597-604. (Pubitemid 36168668)
22. Martin-Gallan P, Carrascosa A, Gussinye M et al. Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic Biol Med 2003; 34: 1563-1574.
23. Atabek ME, Keskin M, Yazici C et al. Protein oxidation in obesity and insulin resistance. Eur J Pediatr 2006; 165: 753-756.
24. Li HY, Hou FF, Zhang X et al. Advanced oxidation protein products accelerate renal fibrosis in a remnant kidney model. J Am Soc Nephrol 2007; 18: 528-538.
25. Shi XY, Hou FF, Niu HX et al. Advanced oxidation protein products promote inflammation in diabetic kidney through activation of renal nicotinamide adenine dinucleotide phosphate oxidase. Endocrinology 2008; 149: 1829-1839.
26. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T et al. Early prediction of IgA nephropathy progression: proteinuria and AOPP are strong prognostic markers. Kidney Int 2004; 66: 1606-1612.
27. Sugiyama H, Kashihara N, Makino H et al. Apoptosis in glomerular sclerosis. Kidney Int 1996; 49: 103-111.
28. Hattori T, Shindo S, Kawamura H. Apoptosis and expression of Bax protein and Fas antigen in glomeruli of a remnant-kidney model. Nephron 1998; 79: 186-191.
29. Zhang W, Khanna P, Chan LL et al. Diabetes-induced apoptosis in rat kidney. Biochem Mol Med 1997; 61: 58-62.
30. Ying WZ, Wang PX, Sanders PW. Induction of apoptosis during development of hypertensive nephrosclerosis. Kidney Int 2000; 58: 2007-2017.
31. Hoffmann S, Podlich D, Hahnel B et al. Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. J Am Soc Nephrol 2004; 15: 1475-1487.
32. Agarwal ML, Taylor WR, Chernov MV et al. The p53 network. J Biol Chem 1998; 273: 1-4.
33. Fries JW, Sandstrom DJ, Meyer TW et al. Glomerular hypertrophy and epithelial cell injury modulate progressive glomerulosclerosis in the rat. Lab Invest 1989; 60: 205-218.
34. Meyer TW, Bennett PH, Nelson RG. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with type II diabetes and microalbuminuria. Diabetologia 1999; 42: 1341-1344.
35. Dalla VM, Masiero A, Roiter AM et al. Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes 2003; 52: 1031-1035.
36. Liu SX, Hou FF, Guo ZJ et al. Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 2006; 26: 1156-1162.
37. Iwao Y, Nakajou K, Nagai R et al. CD36 is one of important receptors promoting renal tubular injury by advanced oxidation protein products. Am J Physiol Renal Physiol 2008; 295: F1871-F1880.
38. Wei XF, Zhou QG, Hou FF et al. Advanced oxidation protein products induce mesangial cell perturbation through PKC-dependent activation of NADPH oxidase. Am J Physiol Renal Physiol 2009; 296: F427-F437.
39. Gill PS, Wilcox CS. NADPH oxidases in the kidney. Antioxid Redox Signal 2006; 8: 1597-1607.
40. Nagata M, Shibata S, Shigeta M et al. Cyclin-dependent kinase inhibitors: p27kip1 and p57kip2 expression during human podocyte differentiation. Nephrol Dial Transplant 1999; 14(Suppl 1): 48-51.
41. Greiber S, Munzel T, Kastner S et al. NAD(P)H oxidase activity in cultured human podocytes: effects of adenosine triphosphate. Kidney Int 1998; 53: 654-663.
42. Asaba K, Tojo A, Onozato ML et al. Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int 2005; 67: 1890-1898.
43. Thallas-Bonke V, Thorpe SR, Coughlan MT et al. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes 2008; 57: 460-469.
44. Brandes RP, Kreuzer J. Vascular NADPH oxidases: molecular mechanisms of activation. Cardiovasc Res 2005; 65: 16-27.
45. Zhang M, Kho AL, Anilkumar N et al. Glycated proteins stimulate reactive oxygen species production in cardiac myocytes: involvement of Nox2 (gp91phox)-containing NADPH oxidase. Circulation 2006; 113: 1235-1243.
46. Frey RS, Rahman A, Kefer JC et al. PKCzeta regulates TNF-alpha-induced activation of NADPH oxidase in endothelial cells. Circ Res 2002; 90: 1012-1019.
47. Kanjanabuch T, Ma LJ, Chen J et al. PPAR-gamma agonist protects podocytes from injury. Kidney Int 2007; 71: 1232-1239.
48. Guo ZJ, Niu HX, Hou FF et al. Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway. Antioxid Redox Signal 2008; 10: 1699-1712.
49. Hou FF, Miyata T, Boyce J et al. Beta(2)-microglobulin modified with advanced glycation end products delays monocyte apoptosis. Kidney Int 2001; 59: 990-1002.
50. Nagai R, Hayashi CM, Xia L et al. Identification in human atherosclerotic lesions of GA-pyridine, a novel structure derived from glycolaldehyde-modified proteins. J Biol Chem 2002; 277: 48905-48912.
51. Sady C, Jiang CL, Chellan P et al. Maillard reactions by alpha-oxoaldehydes: detection of glyoxal-modified proteins. Biochim Biophys Acta 2000; 1481: 255-264.
52. Mundel P, Reiser J, Zuniga Mejia BA et al. Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 1997; 236: 248-258.
53. Foster RR, Saleem MA, Mathieson PW et al. Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocytes. Am J Physiol Renal Physiol 2005; 288: F48-F57.
54. Yu D, Petermann A, Kunter U et al. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol 2005; 16: 1733-1741.
55. Shihab FS, Andoh TF, Tanner AM et al. Expression of apoptosis regulatory genes in chronic cyclosporine nephrotoxicity favors apoptosis. Kidney Int 1999; 56: 2147-2159.
56. Bitzer M, von GG, Liang D et al. A mechanism of suppression of TGF-beta/ SMAD signaling by NF-kappa B/RelA. Genes Dev 2000; 14: 187-197.
57. Whaley-Connell AT, Chowdhury NA, Hayden MR et al. Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am J Physiol Renal Physiol 2006; 291: F1308-F1314.
58. Moeller MJ, Soofi A, Hartmann I et al. Podocytes populate cellular crescents in a murine model of inflammatory glomerulonephritis. J Am Soc Nephrol 2004; 15: 61-67.
59. Ma LJ, Marcantoni C, Linton MF et al. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 2001; 59: 1899-1910.
60. Sterio DC. The unbiased estimation of number and sizes of arbitrary particles using the disector. J Microsc 1984; 134: 127-136.
61. Bertram JF. Analyzing renal glomeruli with the new stereology. Int Rev Cytol 1995; 161: 111-172.
62. Nyengaard JR. Stereologic methods and their application in kidney research. J Am Soc Nephrol 1999; 10: 1100-1123.
63. Gundersen HJ, Jensen EB. The efficiency of systematic sampling in stereology and its prediction. J Microsc 1987; 147: 229-263.
64. Li JM, Mullen AM, Yun S et al. Essential role of the NADPH oxidase subunit p47(phox) in endothelial cell superoxide production in response to phorbol ester and tumor necrosis factor-alpha. Circ Res 2002; 90: 143-150.
65. Wolf G, Neilson EG. Angiotensin II as a renal growth factor. J Am Soc Nephrol 1993; 3: 1531-1540.
66. Ziyadeh FN. Mediators of diabetic renal disease: the case for tgf-beta as the major mediator. J Am Soc Nephrol 2004; 15(Suppl 1): S55-S57.
67. Vaziri ND. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens 2004; 13: 93-99.